15 Dec 06
With drug pipelines yielding fewer blockbusters and profits from branded drugs being increasingly eroded by generic incursion, pharmaceutical companies are looking to maximize the return on investment of their drugs that do make it to market. Consequently, reformulation has become a common defense by drug makers to prolong the lifecycle of their top sellers.
12 Dec 06
Frost & Sullivan, along with their panel of distinguished industry experts, will take a look at the changing dynamics in today's U.S. pharmaceutical industry. The panel will review traditional adherence programs, examine what is and is not working, and what the next steps are toward addressing the multiple barriers contributing to non-adherence.
For additional information, please visit http://ebroadcast.frost.com/loyalty
10 Nov 06
The treatment of asthma and COPD has dramatically improved following the increased use of fixed dose inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) combination therapies. Although Advair dominates the total asthma/COPD market, Symbicort's recent US approval and Chiesi's recent European approval of an ICS/LABA combination drug, signal a major change in the market dynamics.
20 Oct 06
While there have been no new treatments approved for systemic lupus erythematosus (SLE) in almost 40 years, there are some promising treatments currently in the development pipeline. Unfortunately, the ambiguity surrounding the requirements of clinical trials is preventing these drugs from being approved. However, faced with few alternatives, that hasn't prevented physicians using them off-label.
17 Oct 06
Itâ€™s another Monday practice meeting, the usual drug representative has been roped in to provide lunch and is cooling her heels waiting for the team to finish morning surgery. The usual non-descript pile of sandwiches from the local bakery is stacked on the table and the registrar who has finished early has already picked the best sandwiches...
Ian Mckenzie - PharmiWeb.com Field Reporter
02 Oct 06
From October 1st 2006 the Employment Equality (Age) Regulations 2006 - is coming in to force, making it illegal in the UK to recruit or select candidates based on their age and to discriminate based on age whilst in employment rather than based on skills and competencies. This will apply to discrimination againt young and old, and it WILL dramatically affect recruitment and employment in the UK.
27 Sep 06
A new DPP-4 inhibitor class of oral anti-diabetic medicines, working by the novel mechanism of incretin enhancement, is poised to revolutionise the management of Type 2 diabetes. Data presented at a recent European Association for the Study of Diabetes meeting suggest they will help fill the unmet need for effective anti-diabetic drugs without unacceptable side effects. Numerous agents are in development with two, Galvus (vildagliptin, Novartis) and Januvia (sitagliptin, Merck) awaiting approval
Olwen Glynn Owen - PharmiWeb Field Reporter
25 Sep 06
Rapra Technologyâ€™s First International Conference on Silicone Elastomers took place in Frankfurt on 19-20 September attracting over 120 delegates from as far away as Australia, Brazil, Russia and the US. Presentations covered silicone elastomer materials, liquid silicone rubber, the processing of silicone elastomers, additives and finishing for silicone elastomers. Delegates praised the breadth of the programme content and the practical nature of many of the papers.
20 Sep 06
The Hellenic Competition Committee has issued GSK with a favorable decision, indicating that it can restrict the supply of pharmaceuticals to wholesalers to prevent parallel importation of these drugs, without breaking competition laws. This is an important step for legally restricting parallel importation from one of Europe's biggest parallel trade markets, as Datamonitor's Dr Mark Belsey discoversâ€¦
20 Sep 06
Running clinical trials and recruiting experienced clinical personnel in the UK has certainly challenged many senior managers and recruiters over the past year. At a recent UK conference, both the Association of the British Pharmaceutical Industry (ABPI) and a UK pharmaceutical website were quoted as stating that there continues to be a skills shortage across all disciplines; a lack of long-term educational investment and less development of the existing talent pool were cited as the main reaso
19 Sep 06
Strategic Research Instituteâ€™s Phase IV Clinical Trials (PCT) conference features a fully packed informational two day event organized into a series of discussions focusing on the major Phase IV and Patient Recruitment/ Retention issues of today.
19 Sep 06
GAIN VALUABLE INSIGHT INTO:
â€˘ How CMSâ€™ movement toward P4P will Impact Healthcare and Payors Nationwide
â€˘ Large Employer HR Strategy: How Aligning Incentives and Creating a Health
â€˘ Information Exchange will Reduce your Healthcare Spend
â€˘ Health Plans: How Data, Transparency and Consumers will Affect your P4P Initiatives
19 Sep 06
Five Presentations from CMS including an Update on the 2007 Landscape
Understanding the Short- and Long-Term Impact of Part D
Strategies for Driving Senior Enrollment
Innovative Approaches to Public & Private Partnerships
Analyzing Patient Perceptions of Out-of-Pocket Costs
The Importance of Pharmacoeconomic Data
Securing Favorable Formulary Coverage in the Part D Environment
The Future of Employer Plans
30 Aug 06
In an earlier field report, we looked at some of the issues surrounding manufacturing process instructions (MPIs) and manufacturing process records (MPRs). I want to look at the issue of recording data in MPRs in more detail, as the format of your MPR has a huge impact on its usability and therefore the error rate.
PharmiWeb.com Field Reporter: Jo Hills
23 Aug 06
Paul Hawkins, the General Secretary for the Health and Beauty Association, tells us his philosophy for career progression and how the H&BAâ€™s new website will help them to progress. The website itself promotes HBAâ€™s attempt to bring Health and Beauty companies together in debating and discussing how to develop and adapt the industry to meet changing customer and consumer needs. Paul hopes the move towards e-business will do just that.
22 Aug 06
You may not exactly be breaking into the gold vaults at Fort Knox, scaling the heights of MI5 Ă la James Bond or hacking into The Pentagon security system, but you want to enter the pharmaceutical industry, which can be nearly as difficult.
08 Aug 06
Andy Sarfas is our mover and shaker of the week. He is the Global Internet Business Manager for Reckitt Benckiser.
08 Aug 06
David Mitchell is the Commercial Director at McNeil Consumer Healthcare, a company that produces remedies for self-treatment available at pharmacies and supermarket stores.
08 Aug 06
Alex Bishop is the IT Business Manager at Pfizer, the largest supplier of medicines to the NHS.
04 Aug 06
Because of the ever-increasing costs of healthcare provision the world over, many governments are enacting legislation to promote generic prescription in order to keep costs down. With drugs worth $160 billion in sales coming off patent by 2015, it would seem a good time to be in the generics industry. However the generics market is not without challenges.
03 Aug 06
Manufacturing Instructions and Records: Operators are expected to follow manufacturing instructions to produce a product that meets the required specification. Typically these instructions will be written by technical experts, the chemical engineers who were responsible for the technology transfer, the process validation and so on.
PharmiWeb.com Field Reporter: Joanna Hills
02 Aug 06
Every sponsor or CRO can expect their countryâ€™s regulatory agency to arrive on their premises periodically to conduct routine inspections. In the UK, for instance, the Medicines and Healthcare products Regulatory Agency (MHRA) conducts routine periodic inspections approximately every three years. Apart from these, the MHRA also conducts â€śfor causeâ€ť and â€śfollow upâ€ť inspections, and they also take part in the third-country inspection program. Because all inspections may be either announced or unan
01 Aug 06
Dr Mark Ballard, the Medical Director of Respiratory and Dermatology Therapeutic Areas at the Novartis Pharmaceuticals Corporation answers our questions about their eczema cream Elidel.
01 Aug 06
Doctors taking part in a survey on Alzheimerâ€™s Disease (AD) management have called for clear and consistent guidelines on diagnosis and treatment of the condition to be drawn up as a matter of urgency. The survey was sponsored by Eisai Europe Ltd and Pfizer Inc, who market the cholinesterase inhibitor Aricept (donepezil), and was presented during the International Conference on Alzheimerâ€™s Disease and Related Disorders.
Olwen Glynn Owen â€“ Pharmiweb Field Reporter
31 Jul 06
The Treasury is aware of a growing trend, which has recently moved into the pharmaceutical sector, for staff to be provided to clients through â€śumbrellaâ€ť or â€ścompositeâ€ť companies. These companies promise a golden scenario of reduced costs to their clients and greater take-home pay to the individuals who work through them.
25 Jul 06
Cognitive behaviour therapy (CBT) combines two very effective kinds of psychotherapy delivered face to face by medical therapists
Jim Melling - PharmiWeb Field Reporter